公开(公告)号：US20160037757A1

公开(公告)日：2016-02-11

申请号：US14620141

申请日：2015-02-11

Applicant: Macau University of Science and Technology

Inventor： Liang LIU ,  Ting LI ,  Kam Wai WONG ,  Zhihong JIANG ,  Hua ZHOU

IPC: A01K67/027 ,  A61K49/00

CPC classification number: A01K67/0278 ,  A01K2207/12 ,  A01K2227/105 ,  A01K2267/01 ,  A01K2267/0368 ,  A61K49/0008 ,  G01N33/573 ,  G01N33/574 ,  G01N2333/91215 ,  G01N2800/102 ,  G01N2800/44

Abstract: The present invention provides an in vivo platform for identifying and determining therapeutic or prophylactic activity of test compounds in delay-type hypersensitivity (DTH) and other inflammatory or cancerous diseases mediated by activation of IKK-βC46A mutants. The in vivo platform of the present invention is a non-human transgenic mammal, e.g., a mouse model, with a site directed mutagenesis at a cysteine residue replaced by alanine in IKK-β protein kinase. The site directed mutagenesis is introduced by a specially designed targeting vector containing a transversion in exon 3 of the Ikbkb genes encoding the IKK-β. The present invention also provides methods for generating the transgenic mammal and for determining and identifying compounds that can inhibit activation of IKK-βC46A mutants.

Abstract translation: 本发明提供了一种用于鉴定和确定延迟型超敏反应（DTH）和通过IKK-和bgr C46A突变体的活化介导的其它炎性或癌性疾病的测试化合物的治疗或预防活性的体内平台。 本发明的体内平台是非人转基因哺乳动物，例如小鼠模型，在IKK-和bgr中被半胱氨酸残基替换为丙氨酸的位点定向诱变; 蛋白激酶。 通过特异设计的靶向载体引入定点诱变，所述靶向载体在编码IKK-＆bgr的Ikbkb基因的外显子3中含有颠换。 本发明还提供了产生转基因哺乳动物以及用于测定和鉴定可以抑制IKK-Bgr C46A突变体活化的化合物的方法。

公开(公告)号：US20150031050A1

公开(公告)日：2015-01-29

申请号：US14455951

申请日：2014-08-11

Applicant: Macau University of Science and Technology

Inventor： Liang LIU ,  Ting LI ,  Kam Wai WONG ,  Zhihong JIANG ,  Hua ZHOU

IPC: G01N33/573

CPC classification number: G01N33/573 ,  A61K31/352 ,  A61K31/4188 ,  G01N33/574 ,  G01N2333/91205 ,  G01N2333/91215 ,  G01N2500/04 ,  G01N2800/102 ,  G01N2800/44

Abstract: Uses and applications derived from the discovery of a novel binding site of IKK-β, such as method of screening a therapeutic agent as drug candidate for treating cancer, inflammation, or other diseases/disorders, are provided.

Abstract translation: 提供了从发现IKK-和bgr的新结合位点衍生的用途和应用，例如筛选治疗剂作为治疗癌症，炎症或其它疾病/障碍的候选药物的方法。

公开(公告)号：US20140315867A1

公开(公告)日：2014-10-23

申请号：US14251664

申请日：2014-04-14

Applicant: Macau University of Science and Technology

Inventor： Liang LIU ,  Ting LI ,  Fenggen YAN

IPC: A61K31/353 ,  A61K31/573

CPC classification number: A61K31/353 ,  A61K31/573 ,  A61K2300/00

Abstract: This invention provides a method of preventing and/or treating thymus degeneration comprising administering an effective amount of dihydromyricetin to a subject in need thereof, in which the degeneration is induced by dexamethasone. In one embodiment, the thymus degeneration is induced during the course of treatment of inflammation by dexamethasone.

Abstract translation: 本发明提供了一种预防和/或治疗胸腺变性的方法，包括向有需要的受试者施用有效量的二氢黄芪素，其中由地塞米松引起变性。 在一个实施方案中，在用地塞米松治疗炎症过程中诱导胸腺变性。